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Abstract
Internal tandem duplication (ITD) mutations in the Fms-related tyrosine kinase 3 (FLT3)
gene (FLT3-ITD) are associated with poor prognosis in patients with acute myeloid leuke-
mia (AML). Due to the development of drug resistance, few FLT3-ITD inhibitors are effective
against FLT3-ITD+ AML. In this study, we show that FLT3-ITD activates a novel pathway
involving p21Cdkn1a (p21) and pre-B cell leukemia transcription factor 1 (Pbx1) that attenu-
ates FLT3-ITD cell proliferation and is involved in the development of drug resistance.
FLT3-ITD up-regulated p21 expression in both mouse bone marrow c-kit+-Sca-1+-Lin-
(KSL) cells and Ba/F3 cells. The loss of p21 expression enhanced growth factor-indepen-
dent proliferation and sensitivity to cytarabine as a consequence of concomitantly enriching
the S+G2/M phase population and significantly increasing the expression of Pbx1, but not
Evi-1, in FLT3-ITD+ cells. This enhanced cell proliferation following the loss of p21 was par-
tially abrogated when Pbx1 expression was silenced in FLT3-ITD+ primary bone marrow
colony-forming cells and Ba/F3 cells. When FLT3-ITD was antagonized with AC220, a
selective inhibitor of FLT3-ITD, p21 expression was decreased coincident with Pbx1mRNA
up-regulation and a rapid decline in the number of viable FLT3-ITD+ Ba/F3 cells; however,
the cells eventually became refractory to AC220. Overexpressing p21 in FLT3-ITD+ Ba/F3
cells delayed the emergence of cells that were refractory to AC220, whereas p21 silencing
accelerated their development. These data indicate that FLT3-ITD is capable of inhibiting
FLT3-ITD+ cell proliferation through the p21/Pbx1 axis and that treatments that antagonize
FLT3-ITD contribute to the subsequent development of cells that are refractory to a FLT3-
ITD inhibitor by disrupting p21 expression.
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Introduction
The cyclin-dependent kinase inhibitor p21Cdkn1a (p21) was originally identified as a mediator
of p53-induced growth arrest [1,2] and regulates the proliferation of diverse cell types by mod-
ulating cell cycle, apoptosis and differentiation [3–5]. However, cells in which p53 is not acti-
vated still utilize p21-dependent cell cycle control [6–8]. P21 is highly expressed in
hematopoietic stem cells (HSCs) and maintains quiescence [8]. The loss of p21 in HSCs
increases cell cycle progression but has only a marginal effect on marrow cellularity or periph-
eral blood cell counts [8]. In contrast, p21 can facilitate the proliferation of normal hematopoi-
etic progenitor cells (HPCs) ex vivo following stimulation with hematopoietic growth factors
[9–12]. These findings suggest that p21 has a differentiation stage-specific function in the
hematopoietic system. In addition to regulating the cell cycle [1,2,6,7,13], p21 can modulate
the activity of a number of transcription factors and co-activators, such as Stat3 [13,14], estro-
gen receptorα[15], (Ccaat-enhancer-binding protein α (C/EBPα) [16,17] and c-Myc [18], sug-
gesting that it may regulate cell fate by influencing gene expression [19].
Internal tandem duplication (ITD) mutations in the Fms-related tyrosine kinase 3 (FLT3)
gene (FLT3-ITD) are found in 20–30% of patients with acute myeloid leukemia (AML) and are
associated with a poor prognosis [20,21]. Few FLT3-ITD inhibitors are effective against
FLT3-ITD+ AML due to the emergence of drug-resistant cells [22,23]. For instance, AC220
(Quizartinib), a second-generation class III tyrosine kinase inhibitor (TKI), which has been used
to treat FLT3-ITD+ AML in clinical trials, is a more potent and specific FLT3-ITD inhibitor
than other TKIs [22,24]; however, prolonged exposure to AC220 could generate FLT3-ITD+
cells that are resistant to AC220 [25]. The mechanisms responsible for drug resistance include
the acquisition of mutations in the FLT3 gene, the activation of other pro-survival pathways and
microenvironment-mediated resistance [22,23]; however, additional mechanisms responsible
for the drug resistance of FLT3-ITD+ AML cells remain to be investigated. Previous studies have
shown that FLT3-ITD enhances p21 expression through Stat5 [26], whereas the FLT3-ITD
inhibitor SU5614 decreases p21 expression in Ba/F3 cells expressing FLT3-ITD [27]. P21 down-
regulation by the FLT3-ITD inhibitor suggests that treatments that antagonize FLT3-ITD may
destroy p21 function and aberrantly affect FLT3-ITD+ cell proliferation. However, the functional
role of p21 in FLT3-ITD signaling and FLT3-ITD-induced drug resistance remains unknown.
In the present study, we identified a p21 signaling pathway downstream of FLT3-ITD that
negatively affects proliferation and is associated with drug resistance in FLT3-ITD+ cells. An
analysis of the genes that are modulated by p21 deletion in FLT3-ITD-transformed HPCs
revealed that p21 modulates the expression of pre-B cell leukemia transcription factor 1
(Pbx1), a proto-oncogene that critically regulates HSC and HPC function [28,29]. Silencing
Pbx1 and p21 expression in FLT3-ITD-transformed HPCs revealed that the interaction
between FLT3-ITD-activated p21 and Pbx1 negatively regulated FLT3-ITD+ HPC prolifera-
tion. In addition, the down-regulation of p21 resulting from FLT3-ITD inhibition by AC220
accelerated the emergence of FLT3-ITD+ cells that were resistant to AC220. This study is the
first report to show how treatments targeting FLT3-ITD can lead to drug resistance.
Materials and Methods
Animals
Specific pathogen-free female C57BL/6 mice, 6–8 weeks of age, were purchased from CLEA
Japan, Inc. (Tokyo, Japan). P21-/- mice were kindly provided by Dr. H.E. Broxmeyer of the
Indiana University School of Medicine [9,10]. Survivinfx/fx mice and Tx-Cre Survivinfx/fx mice
have been described previously [30]. The IACUC of the Shimane University School of
Growth-Inhibitory Signaling in FLT3/ITD+ AML
PLOSONE | DOI:10.1371/journal.pone.0158290 July 7, 2016 2 / 26
20390298 to SF; Japan Society for the Promotion of
Science [https://www.jsps.go.jp/] grant number
25461593 to SF; Japan Leukemia Research Fund
[http://flrf.gr.jp/] to SF; Research Support Funds from
the Mochida Memorial Foundation for Medical and
Pharmaceutical Research [http://www.mochida.co.jp/
zaidan/] to SF; Sankyo Biomedical Research
Foundation and the Mitsubishi Pharma Research
Foundation [http://www.ds-fdn.or.jp/] to SF;
AstraZeneca Research Grant [http://www.
astrazeneca.co.jp/] to SF; Naito Foundation [https://
www.naito-f.or.jp/jp/index.php] to SF. The funders had
no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Medicine (Permit Numbers IZ21-24, IZ21-25, and IZ21-26) and the Indiana University School
of Medicine (Study Number 2939) approved all of the experimental procedures.
Antibodies and cytokines
Anti-FcγIII/II receptor antibody, allophycocyanin (APC)-conjugated anti-mouse c-kit anti-
body (clone 2B8), phycoerythrin (PE)-conjugated Annexin V and PE-Cy7-conjugated anti-
Sca-1 antibody (E13-161.7), along with streptavidin-APC-Cy7, rat IgG2a, rat IgG2b, 7-actino-
mycin-D (7-AAD) and anti-p27 monoclonal antibodies were all purchased from BD Biosci-
ences (San Diego, CA). Biotinylated antibodies against lineage markers, including CD5, B220,
CD11b, Gr-1, 7–4 and Ter119, were purchased from Miltenyi Biotec (Auburn, CA). The anti-
phospho-FLT3 antibody (Tyr591 33G6) and PE-conjugated anti-rabbit IgG (Fab’) were
obtained from Cell Signaling (Danvers, MA). Hoechst 33342 was purchased fromMolecular
Probes (Eugene, OR). Recombinant murine (rm) interleukin-3 (IL-3), recombinant human
(rh) Fms-related tyrosine kinase 3 (FLT3) ligand (FL) and rh-thrombopoietin (TPO) were
obtained from R&D Systems (Minneapolis, MN). Rm-stem cell factor (SCF) was purchased
from BioVision Research Products (Mountain View, CA). Pyronin Y, AG1296, PD98059 and
LY294002 were obtained fromWako Pure Chemical Industries (Osaka, Japan). AC220 (Qui-
zartinib) was obtained from Selleckchem.com (Houston, TX). An Akt inhibitor, etoposide, and
pifithrin-α were purchased from Calbiochem (Gibbstown, NJ). H89 was purchased from
Upstate Biotechnology (Lake Placid, NY). The anti-actin (I-19) and anti-p21 (F-5) antibodies
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture, plasmid transfection, retroviral transduction and shRNA
knockdown
Ba/F3 cells expressing wild-type human FLT3 or FLT3-ITD have been described previously
[30–32]. Retroviral transduction of human wild-type FLT3 and N51-FLT3-ITD in an
MSCV-IRES-EGFP vector into mouse bone marrow cells was performed as previously
described [9,30]. After sequential infections, the GFP+ cells were sorted using a FACSAria II
flow cytometer (BD Biosciences), and 25,000 GFP+ cells were cultured in semisolid methylcel-
lulose or 0.3% agar with 30% heat-inactivated fetal bovine serum (HI-FBS) without hematopoi-
etic growth factors. Colony formation was scored after 7 or 14 days. In replicate liquid cultures,
cells were stained for c-kit, Sca-1 and standard lineage markers at the time of plating or after
incubation in liquid culture. For shRNA-mediated knockdown of Pbx1, bone marrow cells
from the p21+/+ and p21-/- mice were transduced with a control shRNA or Pbx1 shRNA
(shRNA-1 or shRNA-2) using a pSINsi-mU6 plasmid (TAKARA Biotechnology, Otsu, Japan).
The sequences of Pbx1 shRNA-1 and shRNA-2 were 5’-CGA TCA ATG CAT ATT TGC A-3’
and 5’-GGA GCA TTC CGA CTA CAG A-3’, respectively. To transduce shRNAs targeted
against p21 and/or Pbx1 into the Flt3-ITD+ Ba/F3 cells, non-transfected Ba/F3 cells were trans-
duced with MSCV-FLT3-ITD (N51)-EGFP using a retrovirus. The GFP-positive cells were
sorted and electroporated with a p21-specific shRNA that had been cloned into the pBAsi-
mU6 Pur DNA vector (TAKARA Biotechnology). The sequence of the p21 shRNA was 5’-
GCA GAT TGG TCT GCA A-3’. Stable transformants were selected with 3 μg/ml puromycin
and frozen for storage. The cells were subsequently transfected with a pSINsi-mU6 plasmid
containing a Pbx1 shRNA, and G418-resistant cells were selected and used for the analyses.
cDNAmicroarrays and quantitative RT-PCR
Lineage-depleted bone marrow cells obtained from the p21+/+ and p21-/- mice were transduced
with MSCV-IRES-EGFP containing N51-FLT3-ITD3. Following transduction, the GFP+,
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c-kit+, Sca-1+, lineage-negative (KSL) cells were isolated by fluorescence-activated cell sorting
(FACS). Freshly isolated control KSL cells from the same donors were used for the subsequent
comparisons. The sorted cells were subjected to a differential mRNA microarray analysis,
which was performed by Miltenyi Biotec (Auburn, CA). Briefly, 250 ng of each cDNA was
used as a template for Cy3 and Cy5 labeling. Equal amounts of the corresponding Cy3- and
Cy5-labeled cDNAs from the p21+/+ and p21-/- cells were combined and hybridized overnight
(17 h at 65°C) to Agilent Whole Mouse Genome Oligo Microarrays according to the manufac-
turer’s protocol. The microarray data have been deposited in the Gene Expression Omnibus
(www.ncbi.nlm.nih.gov/geo/: GSE75200). In separate experiments, the total RNAs isolated
from sorted p21+/+ and p21-/- KSL cells, with or without FLT3-ITD, were reverse transcribed
and mixed with Power SYBR Green PCR SuperMix (Applied Biosystems, Foster City, CA) for
quantitative RT-PCR (Q-RT-PCR). The PCR primers were: Pbx1, 5’-AAGCCGGACCAGG
CCCATCT-3’ and 5’-GGCCTCGCACGTGCTCTGTT-3’; Evi-1, 5’-GCAGCGACATGTGCG
CAACA-3’ and 5’-GAGGCGAGGACGTTGCCGTC-3’; p21, 5’-GTACTTCCTCTGCCCTGC-
3’ and 5’-AGAGTGCAAGACAGCGACAA-3’; and Hprt, 5’-TGGACAGGACTGAAAGACTT
GCTCG-3’ and 5’-GGCCACAATGTGATGGCCTCCC-3’. The PCR cycling parameters were
95°C for 10 min, followed by 50 cycles at 95°C for 15 s and 60°C for 1 min. The differences in
the mRNA levels were calculated using the ΔCT method and were normalized toHprt.
Statistical analysis
The data are expressed as the means ± standard errors of the mean (SEM). Significant differ-
ences were determined using a two-tailed Student’s t-test in Microsoft Excel™ (Microsoft Corp.,
Seattle, WA).
Results
FLT3 signaling up-regulates p21Cdkn1a expression in Ba/F3 cells through
the p53, PI3 kinase and PKA pathways
We previously showed that FLT3-ITD mutations increase Survivin expression in mouse Ba/F3
cells [30] and that Survivin enhances the proliferation of primary mouse HPCs through
p21-dependent and p21-independent mechanisms [9]. Although p21 negatively regulates cell
proliferation in a variety of cell systems [6–8], these findings suggest that p21 may positively
regulate FLT3-ITD signaling, similar to Survivin. We first investigated the association between
p21 expression and cell proliferation in response to normal FLT3 and FLT3-ITD signaling. In
IL-3-dependent Ba/F3 cells expressing wild-type human FLT3 (Ba/F3-FLT3), IL-3 withdrawal,
which generally induces G1 arrest, resulted in down-regulation of the p21
Cdkn1a protein and
up-regulation of p27 Cdkn1b, a protein that normally inhibits the G1/S transition [33,34] (Fig
1A). The stimulation of Ba/F3-FLT3 cells with FLT3 ligand (FL) concomitantly increased p21
protein levels and total cell number (Fig 1B). The ectopic expression of FLT3-ITD in Ba/F3
cells (FLT3-ITD+ Ba/F3) significantly enhanced cell proliferation (Fig 1C). These changes were
coincident with the up-regulation of p21 and Survivin levels and a reduction in p27 Cdkn1b lev-
els compared to cells expressing wild-type FLT3 (Fig 1D, upper panel). Consistent with the up-
regulation of the p21 protein, p21mRNA expression was significantly increased in FLT3-ITD+
Ba/F3 cells compared to cells expressing wild-type FLT3 (Fig 1D, middle panel). However, the
selective FLT3-ITD inhibitor AC220 [24] significantly decreased p21mRNA expression in
FLT3-ITD+ Ba/F3 cells (Fig 1D, lower panel). Similarly, treatment of FLT3-ITD+ cells with
AG1296, which inhibits FLT3 kinase [35], decreased p21 expression (not shown). Consistent
with the FLT3-ITD+ Ba/F3 cells, increased levels of the p21 protein were also observed in
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Fig 1. FLT3 Signaling Up-regulates p21Cdkn1a Expression in Ba/F3 Cells. (A) Expression of p21 and p27 in Ba/
F3-FLT3 cells before and after IL-3 withdrawal. The blots are from triplicate cultures. The total number of viable cells was
enumerated at the time of harvest using the trypan blue exclusion assay, and lysates from 5x105 viable cells were loaded
into each lane. The p21/p27 ratio was determined by densitometry and is shown beneath the blot. (B) The number of
viable Ba/F3-FLT3 cells stimulated with or without FL. Following IL-3 withdrawal for 16 h, the cells were resuspended in
10% FBS/RPMI-1640 at a concentration of 5x105 cells/ml with FL concentrations ranging from 0 to 200 ng/ml. The number
of viable cells was counted 24 and 48 h after incubation. P21 protein expression was analyzed byWestern blotting at 48 h
(top). The data are representative of two experiments with identical results. (C) Proliferation of Ba/F3 cells expressing wild-
Growth-Inhibitory Signaling in FLT3/ITD+ AML
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FLT3-ITD+ MV4-11 human acute leukemia cells compared to RS4;11 cells expressing wild-
type FLT3 (Fig 1E). The transduction of FLT3-ITD into mouse bone marrow cells and culture
in the absence of hematopoietic growth factors for 14 days resulted in an expansion of c-kit+,
Sca-1+, lineage-negative (KSL) cells as previously reported [30] (not shown), along with a sig-
nificant up-regulation of the p21mRNA in KSL cells (Fig 1F). These data indicate that p21
expression is up-regulated by FLT3 signaling, and similar to Survivin, the increase is associated
with enhanced or accelerated cell proliferation.
Because p21 is one of the major transcriptional targets of p53 [1,36], we next investigated
whether p53 is involved in the up-regulation of p21 induced by FLT3-ITD (Fig 2A). Incuba-
tion of BaF3 cells with etoposide, which activates p53 [37], increased p21 protein levels, indi-
cating that p53 is functional in Ba/F3 cells. Etoposide-enhanced p21 expression was abrogated
by the p53 inhibitor pifithrin-α [1,38], and FLT3-ITD+ Ba/F3 cells treated with pifithrin-α
also down-regulated p21 expression in the absence of etoposide. These results suggest that the
up-regulation of p21 in FLT3-ITD+ Ba/F3 cells is mediated by p53. To identify additional sig-
naling pathways that regulate the p21 expression induced by FLT3-ITD, Ba/F3 cells express-
ing several different human FLT3-ITD constructs were incubated with inhibitors of mitogen-
activated protein kinase (MAPK)p42/p44 (PD98059), phosophoinositide-3 (PI3) kinase
(LY294002) and protein kinase A (PKA) (H89). Although the MAPK inhibitor had little effect
on p21 protein expression, the PI3 kinase and PKA inhibitors reduced p21 levels. Consistent
with the results obtained using FLT3-ITD+ Ba/F3 cells, the PI3 kinase and PKA inhibitors
reduced p21 expression in human FLT3-ITD+ MV4-11 leukemia cells (Fig 2B). These data
indicate that the p53, PI3 kinase and PKA pathways mediate the FLT3-ITD-induced up-regu-
lation of p21.
FLT3-ITD attenuates the growth factor-independent proliferation and cell
cycle progression of hematopoietic progenitor cells by up-regulating
p21Cdkn1a expression
The concurrent enhancement of cell proliferation and p21 up-regulation by FLT3-ITD sug-
gested that p21 may positively regulate FLT3-ITD-potentiated cell proliferation, which was
similar to our previous observations for the endogenous anti-apoptotic protein Survivin [30].
Therefore, we compared the functional roles of p21 and Survivin in the FLT3-ITD-induced
growth factor-independent proliferation of HPCs. Although wild-type FLT3 failed to support
the proliferation of colony-forming cells (CFCs), FLT3-ITD overexpression in control Survi-
vinfx/fx or p21+/+ bone marrow cells resulted in CFC proliferation in the absence of
type or FLT3-ITD. The cells were washed three times and cultured for 72 h in 1% FBS/RPMI-1640, and the numbers of
viable Ba/F3 cells expressing wild-type or FLT3-ITD derived from 3 different patients (N51, N73 and N78) were counted
every 24 h (*: P < 0.05). The data shown are from one of three experiments that were performed in triplicate with identical
results. (D) The upper panel shows the expression of the p21, Survivin and p27 proteins, as analyzed byWestern blotting.
The level of p21 relative to actin is shown beneath the blot. The middle panel shows the relative p21mRNA expression
levels in Ba/F3 cells expressing wild-type or N51-FLT3-ITD, which were determined using quantitative RT-PCR. The
presented data are the averages of two independent experiments (*: P < 0.05). The lower panel shows the p21mRNA
expression levels in FLT3-ITD (N51) Ba/F3 cells incubated with 1 or 2 nM AC220 for 48 h compared to the control cells,
which were incubated with dimethyl sulfoxide (DMSO) alone (N = 3, *: P < 0.05). (E) The blot shows p21 protein
expression in RS4;11 cells and MV4-11 cells, as determined byWestern blot analysis. (F) The p21mRNA expression
levels in FLT3-ITD+ KSL cells compared to freshly isolated bone marrow KSL cells. C57BL/6 mouse bone marrow cells
were retrovirally transduced with N51-FLT3-ITD using the MSCV-IRES-EGFP vector and were cultured for 2 weeks
without hematopoietic growth factors. The GFP+ KSL cells were sorted by FACS, and p21mRNA expression was
compared with freshly isolated KSL cells from the same donor. The presented data are the averages of three independent
experiments (*: P < 0.005).
doi:10.1371/journal.pone.0158290.g001
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Fig 2. Up-regulation of p21 Expression Induced by FLT3-ITD is Mediated through the p53, PI3 Kinase
and PKA Pathways. (A) Ba/F3 cells expressing wild-type FLT3 were incubated with 20 μM pifithrin-α for 24
h, followed by exposure to 1 or 5 μM etoposide for 2.5 h. Ba/F3 cells expressing N51-FLT3-ITD were also
incubated with pifithrin-α for 24 h. The cell lysates were subjected to Western blot analysis to determine the
p21 protein expression levels. (B) Ba/F3 cells containing N51, N73 and N78 FLT3-ITD were incubated with
the indicated concentrations of DMSO, PD98059, LY294002 or H89 (all of which were diluted in DMSO) in
10% FBS/RPMI-1640 supplemented with 0.1 ng/ml rmIL-3 for 24 h. Human MV4-11 leukemia cells harboring
endogenous FLT3-ITD were treated in the same manner and were incubated in 10% FBS/RPMI-1640. The
Growth-Inhibitory Signaling in FLT3/ITD+ AML
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hematopoietic growth factors (Fig 3A). Conditional deletion of Survivin reduced the growth
factor-independent proliferation of FLT3-ITD-transduced CFCs, as previously reported (Cre-
ER Survivinfx/fx in Fig 3A) [30]. In contrast, deletion of the p21 gene increased the prolifera-
tion of CFCs transduced with FLT3-ITD (Fig 3A). An intermediate number of CFCs was gen-
erated by p21+/- cells transduced with FLT3-ITD, indicating that the effect of p21 was gene
dosage-dependent (Fig 3A, inset). Similar to CFCs, the growth factor-independent prolifera-
tion of FLT3-ITD+ KSL and c-kit+, lineage-negative (KL) cells was further enhanced by the
deletion of p21 (P< 0.05, Fig 3B). In contrast, the loss of p21 did not significantly affect cell
number or the proportion of lineage-positive and lineage-negative cells. Although no differ-
ence was observed in the number of apoptotic cells between the FLT3-ITD+ p21+/+ KL and
FLT3-ITD+ p21-/- KL cells, the enhancement of FLT3-ITD+ cell proliferation by p21 deletion
was associated with a marginal but significant increase in the number of cells in S+G2/M
phase (18.2 ± 0.5%) compared to p21+/+ cells (15.3 ± 0.8%, P< 0.05, N = 3), concomitant
with increased levels of Ki-67, a marker for cycling cells (1.5 ± 0.1-fold increase, P< 0.01,
N = 3). In contrast, ectopic p21 overexpression decreased the number of growth factor-inde-
pendent FLT3-ITD+ KSL cells derived from the control cells compared to cells expressing
FLT3-ITD alone (P< 0.05). The loss of Survivin (Cre-ER Survivinfx/fx) further reduced the
number of FLT3-ITD+ KSL cells overexpressing p21 (Fig 3C). Similarly, treatment with a p21-
specific shRNA increased the growth factor-independent proliferation of FLT3-ITD+ Ba/F3
cells compared to treatment with a control shRNA and was coincident with a marginal but
significant increase in the number of cells in S+G2/M phase (Fig 3D). Moreover, p21 silencing
increased the sensitivity of FLT3-ITD+ Ba/F3 cells to the cell cycle-specific chemotherapeutic
agent cytarabine (Ara-C) (Fig 3E) [39]. The 50% inhibitory concentrations (IC50s) of Ara-C
were 0.6 and 0.27 μM in the control FLT3-ITD+ Ba/F3 cells and those transduced with p21
shRNA, respectively. These data suggest that the FLT3-ITD-mediated up-regulation of p21
inhibits FLT3-ITD+ cell proliferation and confers resistance to chemotherapy by delaying cell
cycle progression.
Blocking p21 by FLT3-ITD inhibition facilitates the emergence of
FLT3-ITD+ cells that are refractory to the FLT3-ITD inhibitor AC220
The poor efficacy of FLT3-ITD inhibitors for FLT3-ITD+ AML [22,23] underscores the need
to investigate the mechanism responsible for the drug-resistant phenotype of FLT3-ITD+
AML. The capacity of the FLT3-ITD-mediated up-regulation of p21 expression to inhibit the
proliferation of FLT3-ITD+ HPCs suggests that FLT3-ITD signaling attenuates the prolifera-
tion and cell cycle progression of FLT3-ITD+ HPCs. However, the p21 down-regulation in
FLT3-ITD+ cells triggered by inhibitors of FLT3-ITD, p53, PI3 kinase, and PKA suggests that
the sustained inhibition of FLT3-ITD or other molecular pathways downstream of FLT3-ITD
may block endogenous anti-growth signaling, possibly contributing to the recurrence of
FLT3-ITD+ AML. To determine whether inhibiting p21 expression in FLT3-ITD+ cells by
antagonizing FLT3-ITD is associated with the proliferation and/or emergence of FLT3-ITD+
cells that are refractory to a FLT3-ITD inhibitor, the association between p21 expression and
cell proliferation was investigated in FLT3-ITD+ cells treated with a FLT3-ITD inhibitor.
FLT3-ITD+ Ba/F3 cells were cultured in the absence of cytokines with 2 or 5 nM AC220, a
p21 expression levels (relative to actin) were quantitated byWestern blot analysis and densitometry. The
histogram beneath the blot indicates the percentages by which p21 expression was reduced by the inhibitors,
which were averaged in 4 wells and determined by a comparison with the DMSO control (*: P < 0.05).
doi:10.1371/journal.pone.0158290.g002
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Fig 3. FLT3-ITD Attenuates the Growth Factor-independent Proliferation and Cell Cycle Progression of
Hematopoietic Progenitor Cells by Up-regulating p21Cdkn1a Expression. (A) Growth factor-independent proliferation of
CFCs in mouse bone marrow cells lacking p21 or Survivin and transduced with FLT3-ITD. Bone marrow cells from Survivinfx/
fx, Cre-ER Survivinfx/fx, p21+/+ or p21-/- mice were retrovirally transduced with wild-type FLT3 or N51-FLT3-ITD. A total of
500,000 GFP+ cells were plated on either 0.3% agar or methylcellulose medium containing 30% FBS in the absence of
hematopoietic growth factors. To delete the Survivin gene, cells from Cre-ER Survivinfx/fx or Survivinfx/fx mice were cultured in
the presence of 1 μM 4-hydroxy tamoxifen at the time of plating. The colonies were enumerated after 14 days. The presented
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selective inhibitor of FLT3-ITD, for 24 hours, and FLT3 phosphorylation was inhibited (Fig
4A). Although the reduced FLT3 phosphorylation was not evident after 24 hours of incuba-
tion with 1 nM AC220, prolonged incubation with 1, 2 or 5 nM AC220 significantly inhibited
the growth-factor independent proliferation of FLT3-ITD+ Ba/F3 cells compared to the con-
trols, suggesting that AC220 antagonizes the growth-stimulatory function of FLT3-ITD (Fig
4B). In contrast, the same treatment significantly decreased p21mRNA expression in the
FLT3-ITD+ cells (Fig 4C), implying that FLT3-ITD inhibition disrupts growth-inhibitory sig-
naling pathways, and not just pathways that stimulate cell proliferation. When the FLT3-ITD+
Ba/F3 cells were incubated with 1 or 2 nM AC220 for more than 8 days, cell proliferation
began to increase despite the presence of AC220 (Fig 4B, left panel). Similarly, the number of
viable cells declined immediately after incubation with 5 nM AC220, but cells began to prolif-
erate after 21 days in the presence of 5 nM AC220 (Fig 4B, right panel), indicating the devel-
opment of FLT3-ITD+ cells that were refractory to AC220, as previously reported [30].
Incubating the AC220-refractory cells with AC220 down-regulated p21 expression (Fig 4C),
suggesting that AC220 can also disrupt growth-inhibitory signaling in AC220-refractory
FLT3-ITD+ cells. However, p21 overexpression in the FLT3-ITD+ Ba/F3 cells significantly
delayed the emergence of AC220-resistant FLT3-ITD+ cells (Fig 5A, left panel) and inhibited
the proliferation of AC220-resistant FLT3-ITD+ cells cultured in the presence of 2 nM AC220
for up to 60 days (Fig 5B). The medium was replaced every 5 days, and fresh AC220 was
added at a concentration of 2 nM; therefore, the emergence of resistant cells was not due to
the loss of AC220 activity. The IC50 for the control FLT3-ITD+ cells was 0.77 nM, whereas
that in the cells expressing ectopic p21 was 0.65 nM on day 10 (Fig 5A, right panel). In con-
trast, p21 silencing with an shRNA significantly delayed the reduction in the number of viable
FLT3-ITD+ Ba/F3 cells induced by AC220 (Fig 6A, left panel) and accelerated the develop-
ment and proliferation of FLT3-ITD+ cells refractory to 2 nM AC220 up to 60 days (Fig 6B).
The IC50 of AC220 for the FLT3-ITD+ cells containing the control shRNA was 0.35 nM on
day 10, whereas p21 silencing increased the IC50 to 0.7 nM (Fig 6A, right panel). These find-
ings suggest that the down-regulation of p21 resulting from FLT3-ITD inhibition facilitates
proliferation and the development of FLT3-ITD+ cells that are refractory to AC220.
data are the averages of 9 experiments for p21 deletion and 2 experiments for Survivin deletion (P < 0.05). The numbers of
CFCs generated by p21+/- cells transduced with FLT3-ITD compared to those generated by p21+/+ and p21-/- cells are shown
in the lower panel. The data shown were obtained from one of two experiments that yielded identical results. (B) The
proliferation of bone marrow c-kit+, Sca-1+, lineage- (KSL), c-kit+, lineage- (KL), lineage- (Lin-) or lineage+ (Lin+) cells
transduced with FLT3-ITD derived from p21+/+ and p21-/- mice. Following transduction, the GFP+ cells were sorted and
cultured in 10% FBS/IMDM in the absence of hematopoietic growth factors. The cells were enumerated 7 days after culture.
The fold change in the number of FLT3-ITD+ p21-/- cells compared to the FLT3-ITD+ p21+/+ cells is shown. The presented
data are the averages of three experiments (P < 0.05). The cell number from one representative experiment is shown in the
lower panel. (C) The effect of ectopic p21 expression on FLT3-ITD+ KSL cell proliferation. Bone marrow cells from control
Survivinfx/fx mice or Cre-ER Survivinfx/fx mice were transduced with N51-FLT3-ITD and p21 using a MIEG3 vector or a
negative MIEG3 vector control. Following transduction, the GFP+ cells were cultured for 2 weeks in 10% FBS/IMDM
containing 1μM 4-hydroxy tamoxifen at a density of 5 x 105 cells/ml. The cells were stained for c-kit, Sca-1 and lineage
markers to quantify the number of KSL cells. The data shown were obtained from one of two experiments that were analyzed
in triplicate. (D) Ba/F3 cells expressing FLT3-ITD (N51) were transduced with either a p21 shRNA or a control shRNA and
were cultured in 1% FBS/RPMI without any growth factors. The viable cells were enumerated using the trypan blue exclusion
assay. The data shown were obtained from one of two experiments that were performed in quadruplicate with identical results
(*: P < 0.01). The expression levels of the p21 protein in both cell lines are shown in the inset. The lower panel shows a cell
cycle histogram of FLT3-ITD+ Ba/F3 cells transduced with a control shRNA (left plot) and the p21 shRNA (right plot). The
histogram represents one of three experiments with identical results. (E) Dose-dependent growth inhibition by Ara-C in
N51-FLT3-ITD-Ba/F3 cells transduced with the p21 shRNA and control cells. The cells were cultured in the presence of
DMSO alone (control) or increasing doses of Ara-C in 1% FBS/RPMI-1640 without any growth factors for 24 hours. The y-
axis represents the % inhibition of viable cells incubated with Ara-C compared to DMSO. The data shown represent one of
three experiments with identical results.
doi:10.1371/journal.pone.0158290.g003
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Fig 4. Blocking FLT3-ITD Using AC220 Decreases p21 Expression Coincident with Emergence of
FLT3-ITD+ Cells Refractory to AC220. (A) The panel shows FLT3 phosphorylation in N51-FLT3-ITD-Ba/F3
cells incubated with 1, 2 or 5 nM AC220 for 24 hours. The cells were stained for phospho-FLT3 using a rabbit
monoclonal antibody raised against Tyr591 of human FLT3, followed by staining with a PE-conjugated anti-
rabbit IgG secondary antibody and flow cytometry analyses. (B) The left panel indicates the numbers of
viable N51-FLT3-ITD-Ba/F3 cells incubated with 1 or 2 nM AC220 compared to the DMSO control (0 nM).
Cells plated at a density of 1 x 105 cells/ml were incubated with 1 or 2 nM AC220 or control DMSO for 12
days. The right panel represents the number of viable cells that were incubated with 5 nM AC220 for 22 days.
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The enhanced proliferation of FLT3-ITD-transformed HPCs following
p21 deletion is associated with up-regulation of Pbx1 expression
In addition to regulating the cell cycle and apoptosis [1,2,6,7,13], p21 can modulate the activ-
ity of a number of transcription factors and co-activators [14–18], suggesting that it may regu-
late cell fate by influencing gene expression [19]. To identify the potential mechanisms by
which p21 attenuates the proliferation of FLT3-ITD+ HPCs, we compared the gene expression
profiles of p21+/+ and p21-/- FLT3-ITD+ KSL cells. In three separate experiments, p21 deletion
in FLT3-ITD+ KSL cells resulted in changes in the expression of 111 distinct mRNAs com-
pared to the p21+/+ FLT3-ITD+ KSL cells, which were either unaffected or differentially regu-
lated in normal bone marrow KSL cells (Table 1 and S1 Table). The 111 genes were
functionally classified based on the biological process subclasses of the Gene Ontology data-
base (Fig 7A). The top 3 functional groups that were associated with p21 include the regula-
tion of transcription (DNA-dependent), cell proliferation and phosphorylation. Among the
111 genes, 12 were deregulated in human AML stem cells (AML-LSC) (Table 1) [40]. These
12 genes were further classified into 8 functional groups based on the Gene Ontology terms
and the Swiss Protein database (Fig 7B). The transcription factor Pbx1, which is associated
with HSC and HPC function [28,29] and is down-regulated in AML-LSC [40], was up-regu-
lated in FLT3-ITD+ KSL cells upon p21 deletion. However, Pbx1 was not affected by p21 dele-
tion in normal KSL cells (see below). Pbx1 itself was classified in 7 of the functional groups
(Fig 7B).
Although the loss of p21 did not significantly affect Pbx1 expression in normal KSL cells
(1.0 ± 0.3-fold change compared to p21+/+ KSL cells, NS), the quantitative RT-PCR analysis
confirmed that Pbx1 was up-regulated by 2.1 ± 0.5-fold in FLT3-ITD+ p21-/- KSL cells com-
pared to FLT3-ITD+ p21+/+ KSL cells (P< 0.001, Fig 8A, left panel). Because Pbx1 expression is
transcriptionally regulated by the transcription factor Evi-1 [41] and FLT3-ITD and because
p21 altered Pbx1 expression, we hypothesized that the changes in Pbx1 expression induced by
FLT3-ITD and/or p21 are mediated by Evi-1. Therefore, we investigated the Evi-1 levels in the
freshly isolated KSL cells and the FLT3-ITD-transformed KSL cells in the presence or absence
of p21. However, p21 deletion had no effect on Evi-1 expression in normal or FLT3-ITD-trans-
formed KSL cells (Fig 8A, right panel). The Pbx1mRNA levels in the p21-/- KSL cells in G0 and
G1 phases were equivalent to those in the p21
+/+ cells (1.0 ± 0.3- and 1.4 ± 0.3-fold changes,
respectively), whereas Pbx1 expression in p21-/- KSL cells in S phase was elevated by
6.1 ± 1.1-fold (P< 0.05, N = 3) compared to the p21+/+ cells (Fig 8B). Because Pbx1 expression
was not modulated by p21 in the absence of FLT3-ITD, we next determined the effect of
FLT3-ITD on Pbx1 expression. FLT3-ITD+ Ba/F3 cells significantly down-regulated Pbx1
mRNA levels compared to FLT3-ITD- Ba/F3 cells (Fig 8C, left and middle panels). Conversely,
the FLT3-ITD inhibitor AC220 significantly up-regulated Pbx1mRNA expression in the
The medium was replaced every 5 days and contained 5 nM fresh AC220. The cells were enumerated using
the trypan blue exclusion assay. The y-axis represents the cell number on the log scale. The data shown
represent one of the three experiments that were analyzed in triplicate with identical results (*: P < 0.05
compared to time 0, †: P < 0.05 compared to 1 or 2 nM AC220). (C) The relative expression of p21 in
N51-FLT3-ITD-Ba/F3 cells that were sensitive or refractory to AC220 and incubated with 2 nM AC220
compared to those incubated with the DMSO control. The refractory cells, which were established by
incubation with 2 nM AC220, were washed and cultured for 48 hours in fresh medium without AC220. The
cells were subsequently incubated with 2 nM AC220 for 48 hours. Similarly, parental cells that were sensitive
to AC220 were incubated with 2 nM AC220 for 48 hours. The p21mRNA levels were quantitated before and
after incubation with AC220 (*: P < 0.05, N = 3).
doi:10.1371/journal.pone.0158290.g004
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Fig 5. Overexpressing p21 Delays the Emergence and Proliferation of FLT3-ITD+ Cells Refractory to AC220.
(A) The numbers of viable N51-FLT3-ITD-Ba/F3 cells transfected with the murine p21 cDNA or control plasmid were
quantitated in the presence or absence of 2 nM AC220. Cells were plated at a density of 1x105 cells/ml and incubated
with 2 nM AC220 or control DMSO for 10 days. The viable cells were enumerated using the trypan blue exclusion
assay. The data shown represent one of three experiments that were analyzed in triplicate with identical results (*:
P < 0.05 compared to the control plasmid). The expression levels of the p21 protein in the control cells and those
transfected with the p21 cDNA are shown above the histogram. The right panel indicates the AC220 dose-dependent
inhibition of the control FLT3-ITD+ cells containing empty vector and those overexpressing p21. The cells were
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incubated with different concentrations of AC220 for 10 days, and the percent inhibition of viable cells was calculated
compared to the control cells incubated with DMSO. (B) The panel indicates the numbers of viable FLT3-ITD+ cells
containing the empty vector or p21 cDNA that were cultured in the presence of 2 nM AC220 for 60 days. The cells
were plated at a density of 1x105 cells/ml and were incubated with 2 nM AC220 or the DMSO control for 60 days. The
medium was replaced every 5 days and contained 2 nM fresh AC220. The y-axes of the histograms are shown in
linear but different scales (*: P < 0.05 compared to the control).
doi:10.1371/journal.pone.0158290.g005
Fig 6. Silencing p21 Accelerates the Emergence and Proliferation of FLT3-ITD+ Cells Refractory to AC220.
(A) The numbers of viable N51-FLT3-ITD-Ba/F3 cells transfected with the p21 shRNA or control shRNA were
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FLT3-ITD+ Ba/F3 cells (Fig 8C, right panel). Although the up-regulation of Pbx1 expression
induced by the loss of p21 in FLT3-ITD+ KSL cells was independent of Evi-1 expression, the
transduction of FLT3-ITD into primary mouse bone marrow resulted in significant decreases in
the Pbx1 and Evi-1mRNA levels compared to their levels in freshly isolated KSL cells (P< 0.01,
N = 3, Fig 8D, upper panel). In addition, we found that the Pbx1 and Evi-1 expression levels
were significantly reduced in the FLT3-ITD+ AML cells (N = 78) compared to FLT3-ITD- AML
cells (N = 190, P< 0.05, Fig 8D, middle and lower panels), which are listed in the GSE1159
dataset (www.ncbi.nlm.nih.gov/geo/) [42]. These results suggest that both p21 and FLT3-ITD
down-regulate Pbx1 expression, although the effect of p21 on Pbx1 is dependent on FLT3-ITD.
Consistent with the concomitant up-regulation of p21 expression and the down-regulation of
Pbx1 expression, we found that p21 expression (CDKN1A; 202284_s_at in GSE1159) was
inversely correlated with Pbx1 expression, but not with Evi-1 expression, in FLT3-ITD+ AML
subjects, particularly those with the FABM1 subtype (r = -0.46, P< 0.01, 212151_at in
GSE1159, Fig 8E, top panel), although this correlation was not evident in other AML subgroups.
In contrast, the association between p21 and PBX1 was not observed in either FLT3-ITD- AML
cells (r = -0.13, GSE1159, Fig 8E, bottom panel) or normal human CD34+ cells (GSE2666,
HG-U133A and GSE30029, www.ncbi.nlm.nih.gov/geo/) [43].
quantitated in the presence or absence of 2 nM AC220. The cells were plated at a density of 1x105 cells/ml and
incubated with 2 nM AC220 or control DMSO for 10 days. The viable cells were enumerated using the trypan blue
exclusion assay. The data shown represent one of three experiments that were analyzed in triplicate with
identical results (*: P < 0.05 compared to the control shRNA). The expression levels of the p21 protein in both cell
populations are shown in the inset (the same blot is shown in Fig 3D). The right panel indicates the AC220 dose-
dependent inhibition of the control FLT3-ITD+ cells containing empty vector and those with shRNA for p21. The
cells were incubated with different concentrations of AC220 for 10 days, and the percent inhibition of viable cells
was calculated compared to the control cells incubated with DMSO. (B) The panel indicates the numbers of viable
FLT3-ITD+ cells containing the empty vector or p21 shRNA that were cultured in the presence of 2 nM AC220 for
60 days. The cells were plated at a density of 1x105 cells/ml and were incubated with 2 nM AC220 or the DMSO
control for 60 days. The medium was replaced every 5 days and contained 2 nM fresh AC220.
doi:10.1371/journal.pone.0158290.g006
Table 1. Fold Changes in the Genes Regulated by p21 Deletion in the FLT3-ITD-transformed KSL Cells.
Gene
symbol
Name Fold change after p21 deletion in
FLT3-ITD+ KSL cells
Number of functional classiﬁcation hits (as
shown in Fig 7A)
Pbx1 Pre-B cell leukemia transcription factor
1
2.1 7
Vegfa Vascular endothelial growth factor A 1.8 4
Trib1 Tribbles homolog 1 (Drosophila) 2.3 4
Skil SKI-like 1.6 3
Tcf4 Transcription factor 4 2.1 2
Rasgrp1 RAS guanyl-releasing protein 1 -2.5 1
Hdgfrp3 Hepatoma-derived growth factor-
related protein 3
1.7 1
P21 deletion in FLT3-ITD+ KSL cells resulted in the modulation of the expression levels of 111 mRNAs that were either unaffected or differentially regulated
in normal bone marrow KSL cells. Of these 111 genes, 12 were deregulated in human AML-LSC [40]. These genes were classiﬁed based on Gene Ontology
terms and the Swiss Protein database (as shown in Fig 7B). Pbx1 was classiﬁed into 7 of the functional groups. The fold changes in the expression levels of
the genes listed in Fig 7B are shown in Table 1.
doi:10.1371/journal.pone.0158290.t001
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Fig 7. Enhanced Proliferation of FLT3-ITD+ KSL Cells by p21 Deletion is Associated with Alteration of
Expression of Genes Linked to Various Biological Functions. (A) The functional classification of the 111
genes regulated by p21 in FLT3-ITD+ KSL cells. These 111 genes were classified based on the Biological
Process subclass of the Gene Ontology database using the DAVID program [44]. The network of representative
biological processes was visualized using Cytoscape [45]. The size of the circle indicates the number of genes in
a given category, and the thickness of the bar represents the redundancy between the groups. All of the gene
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Pbx1 knockdown abrogates the enhanced proliferation of FLT3-ITD+
HPCs induced by p21 deletion
Because the enhanced proliferation of FLT3-ITD+ HPCs induced by the loss of p21 was accom-
panied by the up-regulation of Pbx1 expression, we next examined whether Pbx1 mediates the
increased proliferation induced by p21 deletion. FLT3-ITD+ p21-/- bone marrow cells trans-
duced with a control shRNA showed a 1.9 ± 0.3-fold increase in the number of growth factor-
independent CFCs compared to p21+/+ cells (P< 0.01, Fig 9A), which coincided with the up-
regulation of Pbx1 expression (Fig 9A, inset). The transduction of two different shRNAs target-
ing Pbx1 into FLT3-ITD+ p21-/- bone marrow cells resulted in reduced Pbx1mRNA levels (Fig
9A, inset) and CFC proliferation in the absence of hematopoietic growth factors compared to
the control shRNA-transduced FLT3-ITD+ p21-/- cells (Fig 9A, shRNA-1: 43 ± 4% reduction,
P< 0.01, N = 3; shRNA-2: 41 ± 7% reduction, P< 0.05, N = 3). The number of CFCs resulting
from the transduction of Pbx1 shRNA into FLT3-ITD+ p21-/- bone marrow cells was compara-
ble to that generated by FLT3-ITD+ p21+/+ bone marrow cells that were transduced with the
control shRNA (NS, N = 3). Similarly, transduction of the Pbx1 shRNAs partially but signifi-
cantly decreased the Pbx1 mRNA levels in the FLT3-ITD+ Ba/F3 cells containing the control
shRNA, along with those harboring the p21 shRNA (Fig 9B, inset, right panel). The enhance-
ment of the growth factor-independent proliferation of FLT3-ITD+ Ba/F3 cells induced by the
p21 shRNA was partially but significantly reduced by transducing these FLT3-ITD+ Ba/F3 cells
with a Pbx1 shRNA (N = 3, Fig 9B and the inset on the top). These data indicate that Pbx1
mediates the enhanced proliferation of growth factor-independent FLT3-ITD+ cells induced
by p21 deletion.
Discussion
The present study shows that FLT3-ITD mutations produce proliferative and anti-growth sig-
nals (Fig 10A). FLT3-ITD concomitantly up-regulated p21 expression and down-regulated
Pbx1 expression. The loss of p21 enhanced the growth factor-independent proliferation and
cell cycle progression of FLT3-ITD+ cells and their sensitivity to Ara-C, suggesting that the
enhanced expression of p21 attenuates cell cycle progression and confers chemoresistance to
FLT3-ITD+ cells. Furthermore, the p21 deficiency promoted the selective up-regulation of
Pbx1 expression in FLT3-ITD+ KSL cells, whereas silencing Pbx1 expression partially abro-
gated the enhanced proliferation of FLT3-ITD+ HPCs induced by p21 deletion, indicating that
the p21-mediated inhibition of the proliferation of FLT3-ITD+ HPCs is mediated, at least in
part, by Pbx1. Importantly, the p21 down-regulation resulting from FLT3-ITD inhibition by
AC220 accelerated proliferation and development of FLT3-ITD+ cells that were refractory to
AC220, suggesting that treatments targeting FLT3-ITD can eradicate growth-inhibitory signals
by inhibiting p21 expression, thereby potentially contributing to FLT3-ITD+ AML progression
(Fig 10B & 10C).
lists and functional categories are shown in S1 Table. The array data have been deposited in the NCBI Gene
Expression Omnibus (GSE75200). (B) The functional classifications of the 12 genes that were regulated by p21
in FLT3-ITD+ KSL cells and deregulated in human AML-LSC [40]. The modulated genes were classified based
on their biological processes and molecular functions, as defined by Gene Ontology terms and Swiss Protein
keywords using the DAVID program [44]. Five of the 12 molecules were not classified. The 8 significantly
enriched functional categories (P < 0.05) were connected and visualized using Cytoscape [45]. PBX1 was
identified in 7 of 8 functional categories. The size of the circle indicates the number of genes in a given category,
and the thickness of the bar represents the redundancy between the groups. The genes that were classified in
each functional category are shown in the box. PBX1 is underlined. The fold changes in the expression levels of
the listed genes are shown in Table 1.
doi:10.1371/journal.pone.0158290.g007
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Fig 8. The Enhanced Proliferation of FLT3-ITD-transformed HPCs Following p21 Deletion is Associated with the
Up-regulation of Pbx1 Expression. (A) The effects of p21 deletion on the Pbx1 and Evi-1mRNAs. The left panel shows
the expression levels of Pbx1mRNA in freshly isolated KSL cells or FLT3-ITD+ KSL cells, which were derived from p21-/-
cells, compared to p21+/+ cells. The expression levels of Pbx1 relative to Hprt in p21-/- KSL and p21-/- FLT3-ITD+ KSL
cells were compared to those in p21+/+ KSL and p21+/+ FLT3-ITD+ KSL cells, respectively, using quantitative RT-PCR (*:
P < 0.001, N = 3). A similar analysis of Evi-1 expression is shown in the right panel (NS, N = 3). (B) The expression levels
of the Pbx1mRNA in p21+/+ and p21-/- FLT3-ITD+ KSL cells at different stages of the cell cycle were compared. Marrow
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Our results indicate that growth factor withdrawal reduces p21Cdkn1a expression in Ba/
F3-FLT3 cells while increasing p27 Cdkn1b expression, and FLT3 ligand and FLT3-ITD up-regu-
late p21 expression but down-regulate p27 Cdkn1b expression. These data clearly support the
differential regulation of p21 and p27 expression in response to FLT3 signaling. The up-regula-
tion of p21 expression by FLT3-ITD was mediated through the p53, PI3 kinase and PKA path-
ways. Our data showed that FLT3-ITD up-regulated p21 expression in HPCs and Ba/F3 cells,
concomitant with their enhanced proliferation. However, the loss of p21 enhanced the prolifer-
ation of FLT3-ITD+ HPCs and Ba/F3 cells, whereas p21 overexpression resulted in the opposite
effect, indicating that although FLT3-ITD enhances HPC proliferation, the concomitant
increase in p21 expression attenuates their proliferation. Therefore, FLT3-ITD harbors both
growth-inhibitory and growth-stimulatory activities (Fig 10A). FLT3-ITD AML cells are char-
acterized by their high proliferation rate and leukocytosis in patients [20, 21]. The presence of
growth-inhibitory signaling downstream of FLT3-ITD appears to be contradictory to the
increased proliferation potential of FLT3-ITD+ AML cells. The majority of the signaling com-
ponents that exist downstream of FLT3-ITD are known to contribute to cell proliferation
[20,21,30], suggesting that growth-stimulatory signaling dominates the p21-mediated inhibi-
tory activity. The primitive KSL hematopoietic population exhibited the maximal increase in
FLT3-ITD+ cell proliferation in response to the loss of p21. In contrast, the effect of the loss of
p21 was minimal in differentiated cells, suggesting that p21 attenuates the proliferation of early
undifferentiated cells, which resemble AML stem cells. This result is in good agreement with
the increased cell cycle progression in HSCs, without altering the marrow cellularity or periph-
eral blood cell counts in p21-deficient mice [8]. A previous report showed that the induction of
cell cycle entry eliminated AML stem cells in Ara-C-treated mice [39]. The enhanced cytotoxic
effect of Ara-C in FLT3-ITD+ Ba/F3 cells induced by p21 silencing suggests that the up-regula-
tion of p21 expression by FLT3-ITD may confer resistance to Ara-C by inducing quiescence in
FLT3-ITD+ AML cells in the patients.
The down-regulation of p21 expression by AC220-mediated FLT3-ITD inhibition acceler-
ated the development of FLT3-ITD+ cells that were refractory to AC220. AC220 down-regu-
lated p21 expression in FLT3-ITD+ cells; however, p21 overexpression in FLT3-ITD+ cells
significantly delayed the emergence of FLT3-ITD+ cells that were refractory to AC220, whereas
p21 silencing resulted in the opposite effect. Our data suggest that the deregulation of p21
expression in FLT3-ITD+ cells contributes to chemoresistance in two distinct ways. FLT3-ITD+
cells undergo quiescence by up-regulating p21 expression, which enhances their resistance to
cells transduced with N51-FLT3-ITD were stained with antibodies for Sca-1, c-kit, and lineage markers, along with
Hoechst 33342 and Pyronin Y. The relative expression levels of the Pbx1mRNA in FACS-sorted KSL cells in G0, G1 and
S phases compared to p21+/+ cells in G0 phase are shown (N = 3). The sorting gate for cell cycle fractionation is shown in
the inset. (C) The relative expression levels of Pbx1mRNA in Ba/F3 cells transduced with N51-FLT3-ITD compared to
those transduced with wild-type FLT3. The left column shows Pbx1 expression in cells without IL-3. The middle histogram
presents the Pbx1mRNA levels in cells cultured with 0.1 ng/ml rmIL-3. The right histogram shows the Pbx1mRNA
expression levels in N51-FLT3-ITD+ Ba/F3 cells incubated with 1 or 2 nM AC220 for 48 hours compared to the DMSO
controls (*: P < 0.05, N = 3). (D) The upper panel shows the p21, Pbx1 and Evi-1mRNA expression levels in FLT3-ITD+
p21+/+ KSL cells compared to normal KSL cells, as determined by quantitative RT-PCR. The percent changes in
expression compared to the control KSL cells are shown (*: P < 0.01, N = 3). The middle and lower panels show the PBX1
and EVI-1 expression levels in human AML cells with or without FLT3-ITD. The PBX1 (middle) and EVI-1 (lower)
expression levels in human FLT3-ITD+ AML cells (N = 78) were compared to those in the FLT3-ITD- AML cells (N = 190)
listed in GSE1159 (excluding patients with FLT3-TKDmutations, www.ncbi.nlm.nih.gov/geo/, *: P < 0.05). (E) The
relationship between p21 and PBX1 in the AML M1 cases with (upper panel) or without (lower panel) FLT3-ITD that are
listed in GSE1159 (www.ncbi.nlm.nih.gov/geo/) was analyzed using Microsoft Excel. The x-axes are displayed in linear
and log scales in the top and bottom panels, respectively. Correlation values of r > 0.4 or < -0.4 were considered to
indicate significant correlations between p21 and PBX1 (P < 0.05).
doi:10.1371/journal.pone.0158290.g008
Growth-Inhibitory Signaling in FLT3/ITD+ AML
PLOSONE | DOI:10.1371/journal.pone.0158290 July 7, 2016 19 / 26
Fig 9. Pbx1 Knockdown Abrogates the Enhanced Proliferation of FLT3-ITD+ HPCs Induced by p21
Deletion. (A) Bone marrow cells from p21+/+ and p21-/- mice were transduced with FLT3-ITD. Following the
sorting of FLT3-ITD+ cells (using GFP as a marker) by FACS, the cells were transduced with a control shRNA or
Pbx1 shRNA (shRNA-1 or shRNA-2) using a pSINsi-mU6 plasmid, and the number of growth factor-independent
CFCs grown in methylcellulose was quantified 14 days later. The data are shown as the fold changes in the
number of CFCs compared to those of FLT3-ITD+ p21+/+ cells transduced with the control shRNA (N = 3).
Identical results were obtained after 1 week of culture. Quantitative RT-PCRwas performed to compare Pbx1
expression relative to Hprt in the Pbx1 shRNA-transduced samples and p21+/+ cells transduced with the control
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conventional chemotherapeutic drugs, such as Ara-C. In contrast, the disruption of the expres-
sion and/or function of p21 resulting from FLT3-ITD inhibition contributes to the emergence
of FLT3-ITD+ cells that are refractory to FLT3-ITD inhibitors. This result suggests that treat-
ments that antagonize p21 function can sensitize FLT3-ITD+ cells to chemotherapy, whereas
treatments that activate p21 may aid in inhibiting the development of FLT3-ITD+ cells that are
refractory to FLT3-ITD inhibitors. Similar to FLT3-ITD-transformed cells, cells containing
Bcr-Abl [46], AML1-ETO [4] and N-RasE12 [47], all of which regulate the proliferation of
myeloid leukemia cells, exhibit increased p21 expression. The loss of p21 facilitates
AML1-ETO-induced leukemogenesis [4] and increases the proliferation of Bcr-Abl-trans-
formed hematopoietic cells [46], suggesting that these oncogenes also contain signaling com-
ponents that negatively modulate the proliferation of leukemia cells. Moreover, the FLT3
ligand and stem cell factor provided by the bone marrow microenvironment [48] up-regulate
p21 expression in Ba/F3-FLT3 cells and human AML cells [10, 11], respectively. Taken
together, these data indicate that p21 expression that is up-regulated by the oncogenes and/or
hematopoietic growth factors derived from the marrow microenvironment may contribute to
the chemoresistance of AML cells.
Our data also indicate that the enhanced proliferation of FLT3-ITD+ cells induced by the
loss of p21 was accompanied by the up-regulation of Pbx1 expression. Pbx1 is a product of a
proto-oncogene that was originally discovered in acute leukemia and critically regulates organ-
ogenesis and hematopoiesis [28]. Pbx1 regulates the self-renewal of hematopoietic stem cells
by maintaining their quiescence, whereas it facilitates the expansion of HPCs by regulating the
function of common myeloid progenitor cells [28,29]. The hyperproliferation of FLT3-ITD+
HPCs and Ba/F3 cells induced by the concomitant loss of p21 and increased Pbx1 expression
was partially abrogated by Pbx1 silencing, indicating that the enhanced proliferation of
FLT3-ITD+ cells resulting from p21 deletion was due, at least in part, to the up-regulation of
Pbx1 expression induced by p21 deletion. The up-regulation of Pbx1 expression induced by
the p21 deletion implies that p21 down-regulates Pbx1 expression in FLT3-ITD+ cells. Interest-
ingly, Pbx1 silencing had little effect on the proliferation of FLT3-ITD+ cells containing the
control shRNA. The data suggest that the involvement of Pbx1 in FLT3-ITD+ cells is likely
more specific for the p21-mediated function, but not necessarily for the proliferation of
FLT3-ITD+ cells in general. The finding that the p21 deletion had no effect on Pbx1 expression
in normal KSL cells suggests that the modulation of Pbx1 expression by p21 is dependent on
FLT3-ITD. Consistent with the FLT3-ITD-dependent modulation of Pbx1 expression follow-
ing the loss of p21, FLT3-ITD decreased Pbx1mRNA expression in KSL and Ba/F3 cells,
whereas AC220 up-regulated the Pbx1mRNA levels in FLT3-ITD+ Ba/F3 cells. Moreover,
PBX1 expression was significantly reduced in the FLT3-ITD+ AML cells compared to cells
shRNA (inset). (B) FLT3-ITD+ Ba/F3 cells (N51) harboring a p21 shRNA or control shRNA were transduced with
a Pbx1-targeted shRNA or control shRNA. The cells were transfected with a p21 shRNA or a control shRNA and
selected in the presence of 3 μg/ml puromycin for 2 weeks. The reduction in p21 expression was validated as
shown in Fig 3D. The cells were then transfected with the control shRNA or two different shRNAs for Pbx1 (Pbx1
shRNA-1 and Pbx1 shRNA-2) and selected with 1 mg/ml G418 for 2 weeks. The reduction in Pbx1mRNA
expression was validated by Q-RT-PCR and shown in the inset (right). The cells were cultured in 1% FBS/RPMI
without any growth factors for 10 days and enumerated using the trypan blue exclusion assay. The data shown
represent one of three experiments that were performed in quadruplicate with identical results (*: P < 0.01
compared to the control shRNA paired with the Pbx1 shRNA). The top inset indicates the fold change in the cell
number on day 10 compared to the FLT3-ITD+ Ba/F3 cells containing two control shRNAs. The inset on the right
demonstrates the fold change in the Pbx1mRNA expression in the FLT3-ITD+ Ba/F3 cells transduced with the
Pbx1 shRNA compared to those transduced with the control shRNA paired with the Pbx1 shRNA (N = 3,
P < 0.05).
doi:10.1371/journal.pone.0158290.g009
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Fig 10. Suggested Roles of P21-mediated Inhibitory Signaling Pathways that Contribute to the Development of
FLT3-ITD+ Cells that are Refractory to AC220. (A) FLT3-ITD stimulates various signaling molecules that promote cell
proliferation or survival, such as MAP kinase, Akt, Stat5 and Survivin [20, 21, 30]. The present study shows that FLT3-ITD
also generates a growth-inhibitory signal through p21, which is partially mediated by Pbx1. Because the signaling activity
that stimulates cell proliferation or survival dominates the p21-mediated inhibitory signal, the FLT3-ITD+ cells proliferate in
the absence of a FLT3-ITD antagonist. (B) Antagonizing FLT3-ITD with AC220 can not only eradicate the growth-
stimulatory signals but also disrupt the growth-inhibitory signals by inhibiting p21 expression. FLT3-ITD+ cells do not
proliferate immediately after incubation with AC220. (C) Prolonged incubation of FLT3-ITD+ cells with AC220 allowed the
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without FLT3mutations. Although FLT3-ITD down-regulated Evi-1, a transcriptional regula-
tor of Pbx1 [41], p21 deletion had no effect on Evi-1 expression, irrespective of the FLT3-ITD
status, suggesting that the p21-dependent modulation of Pbx1 expression is independent of
Evi-1. Because p21 deletion in FLT3-ITD+ HPCs marginally increased the percentage of cells
in S+G2/M phase and the expression of Pbx1 was higher in S phase than in G1 phase, Pbx1 up-
regulation might be a consequence of cell cycle alterations induced by p21. A search of the
chromosome 1 genomic contig of theMus musculus strain C57BL/6J (MGSCv37 C57BL/6J: gi|
149245775) uncovered a potential non-coding sequence in the 5’ region of the mouse Pbx1
gene. A transcription factor-binding analysis using up to 2.0 kb of the identified 5’ non-coding
sequence revealed candidate binding sequences for c-Myc, C/EBP-α and estrogen receptor-α,
which are known to be directly regulated by p21 [15,17,18]. This result implies that c-Myc, C/
EBP-α or estrogen receptor-αmay be involved in the p21-induced transcriptional regulation of
Pbx1.
Conclusions
Our data demonstrate that FLT3-ITD attenuates FLT3-ITD+ cell proliferation by modulating
the p21/Pbx1 axis. Although the FLT3-ITD-mediated increase in p21 expression increases
resistance to Ara-C by reducing cell cycle progression, disruption of p21 expression using an
FLT3-ITD inhibitor accelerates the development of refractory FLT3-ITD+ cells. This result
suggests that the deregulated expression of p21 and/or Pbx1 by FLT3-ITD likely contributes to
the refractory phenotype of FLT3-ITD+ AML cells. P21 and/or PBX1 may represent additional
therapeutic targets for patients with FLT3-ITD+ AML, particularly those who are refractory to
FLT3-ITD inhibitors.
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cells to re-proliferate, indicating that the cells acquire resistance to AC220, which is most likely mediated by the activation of
stimulatory signals and/or disrupting the growth-inhibitory signals. Our data show that antagonizing FLT3-ITD with AC220
can decrease p21 expression and functions as a growth-inhibitory signal. Although p21 inactivation is not sufficient to
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